2 Top Value Stocks to Own in 2021 | The Motley Fool
Author Bio George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies. Follow @BudwellGeorge Despite a pandemic and a worldwide economic recession, U.S. stocks turned in a banner year in 2020. The iShares Nasdaq Biotechnology ETF, for instance, gained 25% last year thanks to a suite of hurricane-force tailwinds. For example, the U.S. Food and Drug Administration approved an astounding 53 novel drugs last year; ...
Source: fool.com